Investing.com -- Shares of vaccine manufacturers Moderna (NASDAQ: MRNA ) and Novavax (NASDAQ: NVAX ) experienced slight declines in early trading on Wednesday, with Moderna down 1% and Novavax falling 1.3%.

This comes as an external panel of experts to the U.S. Centers for Disease Control and Prevention (CDC) proposed a change in vaccination recommendations on Tuesday.

The panel suggested that updated COVID-19 shots should only be given to those at risk of severe disease.

If adopted, this would be a shift from the current CDC guidelines, which recommend everyone aged six months and older receive an updated COVID-19 shot.

The proposal by the panel is still under consideration and the CDC has yet to officially change its guidelines.

The potential change could impact the demand for vaccines produced by companies like Moderna and Novavax.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.